Stability and compatibility of recombinant adeno-associated virus under conditions commonly encountered in human gene therapy trials

Human Gene Therapy Methods

Volumn 26, Issue 2, 2015, Pages 71-76

  Gruntman, Alisha M ^a   Su, Lin ^b   Su, Qin ^a   Gao, Guangping ^a   Mueller, Christian ^a   Flotte, Terence R ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; GADOLINIUM; POLYETHYLENE; POLYPROPYLENE; POLYSTYRENE; STAINLESS STEEL; CAPSID PROTEIN; RECOMBINANT PROTEIN;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; INVERTED TERMINAL REPEAT; MOUSE; NONHUMAN; PH; PRIORITY JOURNAL; RADIATION EXPOSURE; TEMPERATURE; ULTRAVIOLET RADIATION; VIRAL GENE DELIVERY SYSTEM; ANIMAL; DEPENDOPARVOVIRUS; GENE THERAPY; GENE VECTOR; GENETICS; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; LONG TERMINAL REPEAT; METABOLISM; PROCEDURES; TRANSGENE;

ADENO-ASSOCIATED VIRUS; MIRIDAE; MUS;

ANIMALS; CAPSID PROTEINS; DEPENDOVIRUS; GENETIC THERAPY; GENETIC VECTORS; HUMANS; HYDROGEN-ION CONCENTRATION; INJECTIONS, INTRAMUSCULAR; MICE; RECOMBINANT PROTEINS; TERMINAL REPEAT SEQUENCES; TRANSGENES;

EID: 84928138531     PISSN: 19466536     EISSN: 19466544     Source Type: Journal    
DOI: 10.1089/hgtb.2015.040     Document Type: Article

References (15)

1. Cideciyan AV, Aleman TS, Boye SL, et al. Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics. Proc Natl Acad Sci USA 2008;105:15112-15117.
2. Cideciyan AV, Aguirre GK, Jacobson SG, et al. Pseudofovea formation after gene therapy for RPE65-LCA. Invest Ophthalmol Vis Sci 2015;56:526-537.
3. Bainbridge JWB, Smith AJ, Barker SS, et al. Effect of gene therapy on visual function in Leber's congenital amaurosis. N Engl J Med 2008;358:2231-2239.
4. Hauswirth WW, Aleman TS, Kaushal S, et al. Treatment of Leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial. Hum Gene Ther 2008;19:979-990.
5. Maguire AM, Simonelli F, Pierce EA, et al. Safety and efficacy of gene transfer for Leber's congenital amaurosis. N Engl J Med 2008;358:2240-2248.
6. Nathwani AC, Tuddenham EGD, Rangarajan S, et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med 2011;365:2357-2365.
7. Nathwani AC, Reiss UM, Tuddenham EGD, et al. Longterm safety and efficacy of factor IX gene therapy in hemophilia B. N Engl J Med 2014;371:1994-2004.
8. Mueller C, Ratner D, Zhong L, et al. Production and discovery of novel recombinant adeno-associated viral vectors. Curr Protoc Microbiol 2012;Chapter 14:Unit 14D.1.
9. Gruntman AM, Bish LT, Mueller C, et al. Gene transfer in skeletal and cardiac muscle using recombinant adenoassociated virus. Curr Protoc Microbiol 2013;Chapter 14: Unit 14D.3.
10. Mueller C, Tang Q, Gruntman A, et al. Sustained miRNA-mediated knockdown of mutant AAT with simultaneous augmentation of wild-type AAT has minimal effect on global liver miRNA profiles. Mol Ther 2012; 20:590-600.
11. Turnbull AE, Skulimowski A, Smythe JA, et al. Adenoassociated virus vectors show variable dependence on divalent cations for thermostability: implications for purification and handling. Hum Gene Ther 2000;11:629-635.
12. Horowitz ED, Rahman KS, Bower BD, et al. Biophysical and ultrastructural characterization of adeno-associated virus capsid uncoating and genome release. J Virol 2013; 87:2994-3002.
13. Calcedo R, Wilson JM. Humoral immune response to AAV. Front Immunol 2013;4:341.
14. Snyder RO, Flotte TR. Production of clinical-grade recombinant adeno-associated virus vectors. Curr Opin Biotechnol 2002;13:418-423.
15. Allay JA, Sleep S, Long S, et al. Good manufacturing practice production of self-complementary serotype 8 adeno-associated viral vector for a hemophilia B clinical trial. Hum Gene Ther 2011;22:595-604.